knowledge -WSS

knowledge

author：knowledge 2025-09-28 21:57:13 - browse：29

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

focus

WSS

Data show record exodus of life scientists from academia

The strategy behind pharma's lawsuits over drug pricing reform

After a drawn out lobbying fight, ARPA

In areas with more Black doctors, Black people live longer

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Mindstrong's demise and the future of mental health care

hotspot

knowledge

focus

Continuity nursing helped my family in our darkest PICU moments

Address the ethical violations that led to 'Three Identical Strangers'

United colonoscopy coverage change 'may cost lives,' doctors say

WATCH: Why do fingernails fall off when they're damaged?

Hollywood unions extend contract negotiations for actors

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Peter Hotez and the public health issue of online harassment

How one patient went off dialysis — and others can too

BioMarin wins approval for gene therapy to treat hemophilia A

The battle over the Brookhaven Landfill on Long Island

hotspot

Colonoscopy at 40? Study finds a possible benefit

Would Medicare drug price negotiations stall in a shutdown?

With FDA staff opposed to Sarepta therapy, top official intervened

With FDA staff opposed to Sarepta therapy, top official intervened

Cloning humans is technically possible. It's curious no one has tried

STAT's guide to the next generation of CAR

leisure time

hotspot

focus

explore